ORMPOramed Pharmaceuticals Inc.
4.810USD+0.42%Mkt Cap: 196.85M $P/E: 1.163d ago
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, wh…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap196.85M $
Enterprise Value149.37M $
Revenue (TTM)0 $
Gross Profit13.00K $
Net Income (TTM)64.05M $
Revenue/Share0.0000 USD
Last Price4.810 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS68403P2039
Valuation
P/E (Trailing)1.16
P/E (Forward)-59.88
PEG—
EV/EBITDA-10.37
EV/Revenue—
P/SInfinity
P/B0.62
EPS (TTM)4.13
EPS (Forward)-0.08
52W Range
2.05088% of range5.190
52W High5.190 USD
52W Low2.050 USD
Profitability
Gross Margin0.65%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin3202.50%
ROE32.07%
ROA27.74%
Growth
Revenue Growth—
Earnings Growth493.50%
Cash Flow & Leverage
Operating CF-9.14M $
CapEx (TTM)1.93M $
FCF Margin—
FCF Yield1.28%
Net Debt-49.88M $
Net Debt/EBITDA3.46
Balance Sheet
Debt/Equity0.00
Current Ratio4.98
Quick Ratio4.85
Book Value/Sh7.684 USD
Cash/Share1.217 USD
Dividends
Fwd Div Rate0.2500 USD
Trail. Div Rate0.0000 USD
Div. Yield5.22%
5Y Avg Yield—
Payout Ratio6.05%
Ex-Div DateJan 16, 2026
Pay DateJan 26, 2026
Splits
Last Split1:12
Split DateJan 23, 2013
Analyst Consensus
Rating—
Target (Mean)6.250 USD
Upside (mean)+29.9%
Target Range6.250 USD – 6.250 USD
# Analysts1
Ownership
Shares Out.40.93M
Float31.77M
Insiders17.65%
Institutions45.10%
Short Interest
Short Ratio3.6d
Short % Float2.37%
Short % Out.2.01%
Shares Short835.49K
Short (prev mo.)877.85K
Technical
SMA 504.241 (+13.4%)
SMA 2003.590 (+34.0%)
Beta1.16
S&P 52W Chg18.16%
Avg Vol (30d)177.29K
Avg Vol (10d)197.90K
Technical Indicators
RSI (14)68.9
MACD0.1309
MACD Signal0.0713
MACD Hist.+0.0596
BB Upper4.764 USD
BB Middle4.310 USD
BB Lower3.856 USD
BB Width21.08%
ATR (14)0.2068 USD
Vol Ratio (20d)0.73x